Background-Recent data suggest that GATA-4 is an antiapoptotic factor required for adaptive responses and a key regulator of hypertrophy and hypertrophy-associated genes in the heart. As a leading cause of chronic heart failure, reversal of postinfarction left ventricular remodeling represents an important target for therapeutic interventions. Here, we studied the role of GATA-4 as a mediator of postinfarction remodeling in rats. Methods and Results-Myocardial infarction, caused by ligating the left anterior descending coronary artery, significantly decreased the DNA binding activity of GATA-4 at day 1, whereas at 2 weeks the GATA-4 DNA binding was significantly upregulated. To determine the functional role of GATA-4, peri-infarct intramyocardial delivery of adenoviral vector expressing GATA-4 was done before left anterior descending coronary artery ligation. Hearts treated with GATA-4 gene transfer exhibited significantly increased ejection fraction and fractional shortening. Accordingly, infarct size was significantly reduced. To determine the cardioprotective mechanisms of GATA-4, myocardial angiogenesis, rate of apoptosis, c-kitϩ cardiac stemlike cells, and genes regulated by GATA-4 were studied. The number of capillaries and stemlike cells was significantly increased, and decreased apoptosis was observed. Conclusion-These results indicate that the reversal of reduced GATA-4 activity prevents adverse postinfarction remodeling through myocardial angiogenesis, antiapoptosis, and stem cell recruitment. GATA-4 -based gene transfer may represent a novel, efficient therapeutic approach for heart failure. (Circ Heart Fail. 2010;3:440-450.)
A dverse left ventricular (LV) remodeling after myocardial infarction (MI) is a major cause of heart failure (HF) and death. [1] [2] [3] The molecular mechanisms of post-MI remodeling process are not fully understood but involve alterations in specific signaling molecules, transcription factors (TFs), and their respective downstream pathways. 3 GATA-4 is a zincfinger TF that functions as a key regulator of numerous cardiac genes, such as atrial natriuretic peptide, B-type natriuretic peptide, ␣-myosin heavy chain, and ␤-myosin heavy chain. 4 GATA-4 is also critical for cardiac development, as homozygous GATA-4 -deficient embryos die within 7 to 10 days post coitum owing to defects in ventral morphogenesis and heart tube formation. 5, 6 Studies of alleles that cause partial loss of GATA-4 function and conditional deletion of GATA-4 have demonstrated it necessary also for the later phases of heart development and morphogenesis. [7] [8] [9] Mutations in the human GATA-4 gene have been identified as genetic causes of congenital heart disease. 10, 11 In the adult heart, GATA-4 seems to have a unique dual role, on the 1 hand as a mediator of the hypertrophic response and as a survival factor on the other. GATA-4 is required for cardiomyocyte response to hypertrophic stimuli 12 and has been suggested as a nuclear effector of the stretch-activated
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hypertrophic program in cultured cardiomyocytes. 4, 13 The sufficiency of GATA-4 to induce a hypertrophic phenotype in vitro and in vivo was demonstrated in GATA-4 -overexpressing myocytes and in transgenic mice that developed concentric cardiac hypertrophy. 12, 14 More recent in vivo observations have revealed an additional cardioprotective role for GATA-4, whose activity is downregulated in response to apoptotic stimuli such as treatment with daunorubicin or doxorubicin 15, 16 ; mice heterozygous for a null Gata4 allele have increased myocyte apoptosis and show significantly enhanced cardiotoxic response to doxorubicin treatment. 16 Furthermore, mice heterozygous for deletion of the second exon of Gata4 develop maladaptive hypertrophy in response to pressure overload, 17 as well as mice with a cardiomyocytespecific conditional deletion of Gata4. 18 In vitro, adenovirusbased transfer of GATA-4 protects myocytes against druginduced apoptosis. 16 Interestingly, cell-based intercellular transfer of GATA-4 protein was shown to improve cardiac function in ischemic cardiomyopathy. 19 Despite these findings implicating a cardioprotective potential for GATA-4, little is known concerning its activity, role, or mechanism of actions in post-MI remodeling.
In this study, we established a therapeutic gene transfer protocol to reverse the decreased GATA-4 activity. Because these experiments revealed that GATA-4 overexpression led to prevention of post-MI HF, we evaluated numerous potential mechanisms and target genes triggering the improvement of LV function and structure by GATA-4 gene transfer after MI.
Methods
All methods used in this work are described in detail in the Materials and Methods section in the online Data Supplement available at http://circheartfailure.ahajournals.org.
Recombinant Adenovirus Vectors
The GATA-4 -overexpressing adenovirus was generated by subcloning the XbaI fragment from the rat GATA-4 cDNA into the Ad1-RSV shuttle vector. 12 
MI and Cardiac Gene Transfer
MI was produced by ligation of the left anterior descending coronary artery (LAD). 20 Adenovirus-mediated gene transfer into the LV free wall was performed as previously described. 20, 21 Recombinant adenovirus (1ϫ10 9 pfu) in a 100-L volume was injected with a Hamilton precision syringe directly into the anterior wall of the left ventricle before ligation of the LAD. The syringe was inserted in 1 site of the LV free wall (apex to base), and then slowly the solution was injected while withdrawing the syringe. The adenoviral gene transfer to the normal hearts was performed with the same technique without ligation of the LAD. All experimental protocols were approved by the animal use and care committee of the University of Oulu.
Echocardiographic Measurements
Transthoracic echocardiography was performed with the Acuson Ultrasound System and a 15-MHz linear transducer. 20, 21 After echocardiography, the animals were euthanized, the hearts were removed, and the cardiac chambers were separated, weighed, and stored at Ϫ70°C for later analysis.
Histology, Immunohistochemistry, and Image Analysis
For histologic analysis, the left ventricles were fixed in 10% buffered formalin solution. Transverse sections of the left ventricle were embedded in paraffin, and 5-m-thick sections were cut from the midsection of the heart, at the level of the papillary muscles. The infarcted area was measured from LV circumference in Masson's trichrome-stained sections with a digital image analysis system. To verify the expression of the transgene, the sections were stained with an anti-GATA-4 -specific antibody. To detect apoptotic cells, a terminal deoxynucleotidyltransferase-mediated dUTP nick endlabeling (TUNEL) assay was performed as previously described. 20 Primary antibodies for von Willebrand factor, Ki-67, and c-kit were used to stain endothelial cells, proliferating cells, and cardiac stem cells (CSCs), respectively.
Isolation of RNA and Protein Extraction
Total RNA from whole LV tissue was isolated by the guanidine thiocyanate-CsCl method, and proteins were extracted as described previously. 20 
Electrophoretic Mobility-Shift Assays
GATA-4 DNA binding activity of whole LV nuclear extracts was assessed by electrophoretic mobility-shift assay (EMSA) with a 30-bp oligonucleotide probe containing the Ϫ90 GATA sites of the rat B-type natriuretic peptide promoter. The nuclear protein was extracted and EMSAs were performed as previously described. 22, 23 
DNA Microarray Analysis and Data Analysis
The quality and integrity of the isolated RNA was monitored by a LabChip kit used with the Agilent 2100 bioanalyzer (Agilent, Santa Clara, Calif). Total RNA (nϭ5 in each group) was used as a template for synthesizing cDNA and for making biotinylated cRNA according to the manufacturer's instructions (Affymetrix, Santa Clara, Calif) as previously described. 21 Data analysis was done with GeneSpring version 7.3.1 software (Agilent) and Bibliosphere PathwayEdition software (Genomatix). 21 Genes were defined as differentially expressed if the fold change was at least 1.5-fold and statistically significant (PϽ0.05). The gene expression profiling data discussed in this publication comply with the MIAME standard and have been deposited in the NCBI's Gene Expression Omnibus (GEO) database and are accessible through GEO Series accession number GSE14848 (available at: http://www.ncbi.nlm. nih.gov/geo/query/acc.cgi?accϭGSE14848).
Analysis of RNA
RNA was analyzed by Northern blot analyses and quantitative real-time polymerase chain reaction with TaqMan chemistry on an ABI 7700 sequence detection system (Applied Biosystems) as previously described. 20 -23 The sequences and probes for RNA detection are provided in supplemental Table I .
Statistics
Results are expressed as meanϮSEM. The data were analyzed with ANOVA followed by a least-significant-difference post hoc test. For comparisons between 2 groups, Student t test was used. TUNEL ϩ and Ki-67 ϩ cells as well as the number of capillaries were examined with nonparametric Kruskal-Wallis and Mann-Whitney-Wilcoxon tests. A P value Ͻ0.05 was considered statistically significant.
Results

Changes of GATA-4 Activity After MI
To investigate the role of GATA-4 as a mediator of postinfarction remodeling, rats were subjected to MI by ligating the LAD. As reported previously, ligation of the LAD progressively decreased ejection fraction (EF) and fractional shortening (FS) and caused LV dilatation as assessed by echocardiography during the 4-week follow-up period. 20 The LV dilatation, thinning of the anterior wall, and hypertrophy of the posterior wall were seen in hematoxylin-eosin-stained myocardial sections. 20 At day 1 after MI, the DNA binding activity of GATA-4, assessed by EMSA, was decreased 69% (PϽ0.001) compared with the sham-operated animals (supplemental Figure IA available at http://circheartfailure.ahajournals.org). At 2 weeks, the GATA-4 DNA binding was significantly upregulated (2.4-fold versus sham, PϽ0.05) and returned to baseline at 4 weeks (supplemental Figure IA) . The GATA-4 mRNA levels did not change during the follow-up period as assessed by Northern blotting (supplemental Figure IB) , indicating that the loss of GATA-4 activity was not related to decreased transcript levels. To study the specificity of the changes in GATA-4 activity, the DNA binding activities of other selected cardiac TFs were measured. In contrast to GATA-4 DNA binding, MI caused a sustained increase in activator protein-1 DNA binding activity, which increased significantly after 1 day (6.0-fold versus sham-operated rats, PϽ0.01, nϭ7 to 8) and remained 4.1-fold higher (PϽ0.05 versus sham, nϭ7) at 2 weeks. No differences in serum response factor binding activity were observed during the 4-week follow-up period (data not shown).
Modulation of In Vivo GATA-4 Activity by Adenoviral Gene Transfer
In view of the post-MI downregulation of GATA-4 activity, we established an in vivo gene transfer protocol to locally increase GATA-4 levels in the left ventricle. 21 Different doses of adenoviral constructs were first tested to maximize the upregulation of GATA-4 activity. A strong activation at the level of gene expression and DNA binding was observed when GATA-4 -expressing adenoviral constructs (see Methods section for details) were injected at 1ϫ10 9 infectious units (pfu) in a 100-L injection volume. The control animals received control virus expressing nls-LacZ at 1ϫ10 9 pfu. The LV GATA-4 mRNA levels increased 11-fold (supplemental Figure IIA , PϽ0.001) in GATA-4 -treated animals compared with LacZ-treated animals 3 days after gene transfer. Furthermore, the GATA-4 -treated hearts showed a 22-fold increase in the LV GATA-4 mRNA levels (supplemental Figure IIA , PϽ0.001) 1 week after gene transfer and an 11-fold increase (supplemental Figure IIA , PϽ0.001) at 2 weeks. Accordingly, the LV GATA-4 DNA binding was increased by 2.5-fold (PϽ0.001) at 3 days, 2.5-fold at 1 week (PϽ0.001), and 1.6-fold (Pϭ0.08) at 2 weeks (supplemental Figure IIA) . This increase in GATA-4 binding was quantitatively comparable with that observed in response to increased pressure overload or LV wall stress in vivo. 22, 23 To confirm the specificity of the gene transfer with respect to GATA-4, the LV DNA binding activity of a nonrelated TF, activator protein-1, was measured. LV activator protein-1 DNA binding activity remained unchanged during the 2-week follow-up period (supplemental Figure IIA) , indicating that the gene transfer specifically activates GATA-4. Finally, the efficiency and localization of the gene transfer was confirmed by immunohistochemistry. Paraffin-embedded LV sections from hearts treated with the GATA-4 and LacZ gene transfer were immunohistochemically stained against GATA-4 3 days after gene transfer. As shown in supplemental Figure IIB , GATA-4 was localized in myocyte nuclei, with considerably stronger staining in the hearts treated with the GATA-4 -overexpressing virus.
Rescue of Post-MI Cardiac Function by GATA-4
We next studied the effects of the gene transfer after MI. Adenoviral gene constructs expressing GATA-4 and nlsLacZ were injected into the LV free wall at 1ϫ10 9 pfu, and LAD was ligated immediately thereafter. Both groups showed markedly increased GATA-4 expression in the periinfarct region 3 days after MI ( Figure 1A ). At this time point, as assessed by echocardiography, there was no significant difference in the cardiac function between the GATA-4 and LacZ-treated hearts (supplemental Table II ), indicating that the infarct size after LAD ligation was the same in both groups. At 2 weeks after MI, FS and EF were significantly increased in the infarcted hearts treated with GATA-4 compared with those treated with LacZ (Figure 1B and 1C; FS: 28Ϯ1% versus 16Ϯ1%, PϽ0.001; EF: 58Ϯ5% versus 38Ϯ3%, PϽ0.001) and did not significantly differ from those of LacZ-treated hearts without MI. Accordingly, thinning of the anterior wall ( Figure 1D ) and LV dilatation ( Figure 1E ) were attenuated. Posterior wall thickness at end-diastole or end-systole did not change significantly, suggesting absence of compensatory hypertrophy (data not shown). Under basal conditions, EF, FS, LV diameter, and anterior or posterior wall thickness were similar in GATA-4-and LacZ-treated hearts ( Figure 1B through 1F) .
Reduction of Infarct Size by GATA-4 Gene Transfer
To determine the effect of GATA-4 on the postinfarction structural changes, the infarct size was assessed from LV circumference in Masson's trichrome-stained histologic sections 2 weeks after MI and gene transfer. Consistent with the improved cardiac function, the size of the infarcted area was significantly reduced, being 45Ϯ4% of LV circumference in the LacZ-treated hearts and 26Ϯ4% in the GATA-4 -treated hearts (Figure 2 , PϽ0.01).
Apoptosis and Cell Proliferation After MI and Gene Transfer
The effect of GATA-4 gene transfer on post-MI apoptosis was assessed by TUNEL in the peri-infarct regions choosing hot spot areas. On day 3, LacZ-treated animals with MI showed a 5-fold increase in apoptosis. The number of TUNELϩ cells was significantly lower in GATA-4-treated hearts with MI ( Figure 5A) . No difference in the number of TUNELϩ cells was observed in GATA-4 -treated hearts without and with MI ( Figure 3A) . Double immunofluorescence staining of TUNELϩ cells showed that they were not positive for cardiomyocyte marker ␣-actinin ( Figure 3A , lower right image). As a recent study suggested that a small subpopulation of replicating adult cardiomyocytes may exist, 24 the number of dividing LV cells was studied by immunohistochemical staining with Ki-67. The whole LV was scanned, and stained cells were counted from 5 highpower fields (40ϫ) in each sample to make the results comparable. The number of Ki-67ϩ cells was similar in the GATA-4-and LacZ-treated hearts with MI at 2 weeks ( Figure  3B ; 3Ϯ1 cells/field versus 4Ϯ1 cells/field, PϭNS). The Ki-67ϩ cells were further subgrouped into myocytes and nonmyocytes on a morphological basis, and no difference was observed in the number of Ki-67ϩ myocytes, either (0.2Ϯ0.1 cells/field versus 0.3Ϯ0.1 cells/field, PϭNS). Moreover, double immunostaining (phosphohistone H3ϩ␣-actinin) staining showed that proliferating cells were not cardiomyocytes ( Figure 3B , lower right image).
Angiogenesis in the GATA-4 -Overexpressing Heart
Growing evidence indicates that the loss of functional capillaries and microvessels is a critical determinant of post-MI remodeling. 25 Therefore, we next investigated whether GATA-4 has an impact on myocardial angiogenesis. Histologic sections were immunohistochemically stained against von Willebrand factor 3 days and 2 weeks after MI and gene transfer, and the number of capillaries was counted from 5 representative fields in the peri-infarct region. In the hearts without MI, the number of capillaries was counted from 5 representative fields in the corresponding region of the LV anterior wall. At 3 days, the number of capillaries was similar in LacZ-and GATA-4 -treated hearts without MI, and no difference was observed between the 2 groups after MI (data not shown). At 2 weeks after MI and gene transfer, the number of capillaries was significantly higher in the GATA-4 -treated hearts with or without MI (Figure 4 ).
Increased Number of c-kit؉ Stemlike Cells in the GATA-4 -Overexpressing Hearts
Recent studies have shown that c-kitϩ CSCs may regenerate functional myocardium after MI. 26 As no difference was observed in the number of proliferating adult cardiac cells, we next studied whether the reduced infarct size in the GATA-4 -treated hearts was related to changes in the number of CSCs. As shown in Figure 5A , the number of c-kitϩ stemlike cells was significantly increased in the infarcted hearts overexpressing GATA-4 (15Ϯ7 cells versus 5Ϯ3 cells, PϽ0.05). Spatial distribution of the cells in the LacZ-and GATA-4 -treated hearts with MI demonstrated that c-kitϩ stemlike cells formed clusters in the peri-infarct region of the GATA-4 -overexpressing hearts ( Figure 5B ).
Analysis of GATA-4 Target Genes
To identify genes regulated by GATA-4 in the heart in vivo, the LV gene expression profiles 3 days after GATA-4 gene transfer were compared with those of LacZ-treated animals. We confirmed selected microarray results by comparison with mRNA levels obtained by Northern blot analysis or reverse transcription-polymerase chain reaction, and similar fold-changes in mRNA levels were observed as shown in supplemental Table III . The microarray analysis identified 361 genes that were upregulated Ͼ1.5-fold in the LV overexpressing GATA-4 compared with LacZ-injected hearts (supplemental Table IV and Figure III) . The major functional groups affected by GATA-4 overexpression were genes related to cell signaling/communication (41 genes), inflammatory/immune response (36 genes), biosynthesis/metabolism (31 genes), cell cycle/division (29 genes), and protein synthesis/turnover/posttranslational modifications (27 genes). Yet, the most transcripts to be upregulated in the GATA-4 -overexpressing hearts were genes with unknown function (66 genes) or expressed sequence tags (51 transcripts). Only 35 genes were downregulated Ͼ1.5-fold, the majority of which were expressed sequence tags (supplemental Table V) . Most of the genes we uncovered have not previously been known to be regulated by GATA-4 in any tissue types. These novel GATA-4 target genes include cell cycle regulators, such as cyclins, B1 and B2, and cyclin-dependent kinase inhibitors 1C and 3. Also, well-known extracellular matrix factors such as procollagen types XII and XVII, fibronectin-1, ␤2-integrin, and tenascin-C and critical regulators of cell signaling, including inducible nitric oxide synthase and Janus kinase (JAK)-2, were among the novel cardiac GATA-4 -sensitive genes. Interestingly, transcriptional regulators including TFs runt-related TF-3 and signal transducer and activator of transcription (STAT)-2 were among the GATA-4 targets. Also, previously known cardiac GATA-4 targets were identified, such as cyclin A2 27 and several genes shown to be modulated by GATA-4 in other cell types, including cyclooxygenase-2, 28 interleukin-6, 29 CCAAT/enhancer binding protein (C/EBP)-dependent TFs C/EBP␤, and C/EBP␦. 30 The complete list of 396 differentially expressed genes was loaded into Bibliosphere PathwayEdition software (Genomatix) to identify potential interactions between GATA-4 -regulated genes. Of those genes, 315 were recognized by the software, and 21 of them were found to have real pathway relations in published research literature (expert-curated cocitations). The interaction map showing potential connections among LV genes regulated by GATA-4 overexpression is shown in Figure 6 .
Finally, we compared gene expression patterns altered in response to GATA-4 gene transfer with those altered by p38 mitogen-activated protein kinase (MAPK) overexpression in the heart in vivo to find potential, novel p38 MAPKregulated GATA-4 targets in the heart. p38 MAPK was selectively activated by adenovirus-mediated gene transfer of wild-type p38␣ and constitutively active upstream kinase MAPK kinase 3B into the left ventricle of adult rats, 21 and gene expression analysis was done 3 days after gene transfer. One hundred twenty-two different genes (printed in bold in supplemental Table III) were found to have significantly altered expression in both experimental models. Upregulation of cyclooxygenase-2, a well-characterized in vitro downstream target of both p38 MAPK and GATA-4, was observed, 28, 31 but mainly novel dual p38 MAPK and GATA-4 targets in the heart were identified, such as tenascin-C, interleukin-6, and cyclins A2, B1, and B2.
Discussion
Postinfarction LV remodeling remains an important treatment target in patients after MI and chronic HF. A key finding of our present study in a rat model of coronary ligation is that GATA-4 overexpression elicited beneficial structural remodeling and subsequent improvement of LV systolic function. We tested several potential cellular mechanisms contributing to the remodeling process and provide evidence that the cardiac-restricted zinc-finger TF GATA-4 is a survival factor that can break the vicious circle of post-MI HF through enhanced myocardial angiogenesis, decreased apoptosis, and increased generation/ recruitment of c-kitϩ cells.
Our results indicate that GATA-4 binding activity is downregulated in response to MI; previous studies have shown that a 50% reduction in GATA-4 levels increases myocyte apoptosis and potentiates cardiac dysfunction in response to anthracyclines. 16 Mice with hypomorphic GATA-4 alleles also have an impaired adaptive response to pressure overload. 17 It is therefore reasonable to suggest that decreased GATA-4 activity may trigger detrimental post-MI events, including myocyte apoptosis and an adaptive response of surviving myocytes. Consistent with this, preventing loss of GATA-4 activity by adenoviral gene transfer blocks progression to HF. Infarcted hearts treated with GATA-4 -expressing vector exhibited strongly improved cardiac function, reduced LV dilatation, and anterior wall thinning. The histologic analysis showed that this was a consequence of reduced infarct size and attenuation of structural remodeling.
Loss of myocardial reperfusion capacity owing to loss of vasculature and reversible microvascular dysfunction is also a critical determinant of post-MI remodeling. 25 Remarkably, both normal and infarcted hearts treated with GATA-4 gene transfer showed a significant increase in myocardial capillary density, indicating that GATA-4 regulates angiogenesis in the adult heart and, when upregulated, is sufficient to induce formation of new capillaries. In addition, our microarray study identified several factors involved in angiogenesis, including zyxin, 32 implicated to have a role in hypertension-induced arterial remodeling, and cyclooxygenase-2, which seems to possess both angiogenic and cardioprotective properties in ischemic heart disease. 33 In view of previous evidence demonstrating the efficiency of angiogenic therapeutics in the prevention of post-MI HF, it is likely that the improved cardiac function, reduced infarct size, and attenuation of remodeling observed here are attributable, in part, to the angiogenic effects of GATA-4. The role of GATA-4 in post-MI angiogenesis has remained unknown but is supported by evidence from different experimental models. [7] [8] [9] 34 It is, however, evident that angiogenesis per se is insufficient to reduce infarct size, which requires either reduced loss of myocytes or regeneration of new myocytes. We observed a decreased rate of apoptosis at an early time point in the GATA-4 -treated hearts with MI. This is highly consistent with the previous studies in GATA-4 -deficient hearts and in cardiomyocytes infected with antisense GATA-4 mRNA. 16 -18 Because no difference in apoptosis was observed at later post-MI time points, cellular proliferation and CSCs as putative mechanisms for GATA-4 -mediated cardioprotection were studied. No difference in the number of Ki-67ϩ cardiomyocytes was observed, suggesting that GATA-4 is not involved in the proliferation of adult cardiomyocytes. In contrast, the number of c-kitϩ CSCs was significantly increased in the GATA-4 -treated hearts with MI. Furthermore, these cells appeared to form clusters in the peri-infarct region, suggesting increased recruitment and a functional role in regenerating myocardium. This finding of a connection between GATA-4 and CSCs is novel but can be interpreted in the context of the findings obtained during embryonic development. The differentiation of embryonic stem cells is induced by GATA factors, 35 and embryonal cardiomyocyte proliferation is impaired by early deletion of Gata4 by nkx-2.5 Cre. 9 GATA-4 has also been reported to be a direct activator of cyclin D2 and Cdk4 transcription and to thereby confer embryonal cardiomyocyte proliferation. 27 In fact, gene expression profiling revealed more regulators of diverse cell cycle events to be regulated by GATA-4, including several cyclins. Given this evidence and the potential of CSCs to differentiate into endothelial cells, myocytes, and smooth muscle cells, 26 it is plausible that the observed increase in the number c-kitϩ cells is related to both the angiogenic and antiremodeling effects of GATA-4.
In view of the previous evidence concerning the role of GATA-4 in cardiac gene expression, we analyzed the gene expression profile of the GATA-4 -overexpressing hearts. To our knowledge, most of these 396 identified genes have not been previously shown to be GATA-4 targets. However, GATA core elements have been identified in the promoters of many of these genes, such as inducible nitric oxide syn- thase. 36 The microarray analysis revealed that GATA-4 overexpression caused a significant transcriptional response among a wide variety of genes belonging to almost all functional classes represented on the array. However, at present, we do not know which genes are direct targets (regulated directly by GATA-4 protein binding to DNA regulatory sequences) or indirect targets of GATA-4 gene action. In addition, GATA-4 has been shown to cooperate with other TFs such as Csx/Nkx2-5, myocyte enhancer factor-2, nuclear factor of activated T cells, and serum response factor. 4 Our results show that GATA-4 overexpression increases cardiac gene expression of C/EBP␤ and C/EBP␦, whose transcriptional activity have been shown to be modulated by GATA-4 in intestinal epithelial cells. 30 When genes found to be regulated in the microarray study were used to create an interaction pathway, C/EBP␤ together with inducible nitric oxide synthase and JAK-2 seems to be a central signaling molecule in this network. Consequently, our data suggest that GATA-4 may be involved in regulation of C/EBP-dependent transcriptional responses in the heart, known to control extracellular matrix gene expression in cardiomyocytes. 37 GATA-4 plays an essential role in transcriptional regulation of hypertrophic growth in the adult heart. The absence of the well-known GATA-4 target genes, especially those related to myocyte hypertrophy, such as atrial natriuretic peptide, ␣-myosin heavy chain, and ␤-myosin heavy chain in our microarray data, are noteworthy. However, no signs of cardiac hypertrophy were observed in the GATA-4 -overexpressing hearts, consistent with the gene expression profile. These findings are also equally consistent with those in mice with GATA-4 deletion, which show unchanged expression of many well-known GATA-4 targets and a somewhat variable pattern of the hypertrophic response. 17, 18 Interestingly, our DNA microarray analysis identified several important regulators of structural remodeling in cardiac hypertrophy as a targets of GATA-4. Specifically, GATA-4 seems to regulate cardiac fibronectin-1, ␤2-integrin, tenascin-C, tissue inhibitor of metalloproteinase-1, and procollagens type XII and XVIII, which all have been shown to modulate extracellular matrix composition. Accordingly, the genes associated with fibrosis showed altered expression in the mice with GATA-4 deletion, concomitant with increased fibrosis after transverse aortic coarctation. 17 All together, these results suggest that GATA-4 may profoundly contribute to subsequent cardiac fibrosis during the LV remodeling process in cardiac hypertrophy.
By comparing gene expression profiles of p38 MAPK overexpression in vivo to differentially expressed genes regulated by GATA-4, 122 different genes were found to have significantly altered expression in both experimental models. Because GATA-4 has been shown to be activated directly by p38 MAPK within several tissue types, 4 we hypothesize that gene expression of, for example, tenascin-C and cyclins A2, B1, and B2, is at least partly regulated by p38 MAPK-mediated GATA-4 activation. In addition to p38 MAPK, our results indicate that GATA-4 regulates the JAK-STAT pathway. JAK-2-kinase and STATs have been shown to be important regulators of angiogenesis, for example, 38 suggesting a central role for JAK-STAT signaling in cardioprotective mechanisms during postinfarction remodeling.
Our study has limitations. We describe here a novel GATA-4 -dependent therapeutic approach for post-MI HF. Because the maximal upregulation of GATA-4 binding activity was reached within a few days after gene transfer and normalized within 2 weeks, it can be assumed that the reported effects at 2 weeks may represent long-term structural and functional effects rather than direct effects of transgene expression. However, the longer-term effects were not evaluated; therefore, it is not known whether cardiac function is preserved or not at 3 months or if survival of the animals is improved by intramyocardial GATA-4 gene transfer. Previous studies have shown that short-term benefits can be Figure 6 . Interrelations of genes regulated by GATA-4 overexpression in the heart. Genes that were significantly changed after GATA-4 gene transfer (supplemental Tables III and IV) were examined with Bibliosphere PathwayEdition software (Genomatix). The pathway was built by using known interactions described in the literature to construct a network of potential biological connections between GATA-4 -regulated genes.
achieved by either cell or gene therapy, whereas the longerterm effects are inconsistent. 39, 40 Therapeutic strategies designed to specifically attenuate postinfarction remodeling would represent a promising new approach to improve the symptoms and prognosis of patients with HF. The majority of basic and clinical studies of cardiac regeneration have recently focused on cell-based therapies. Much less attention has been paid to novel approaches that locally induce myocardial protection, regeneration, and angiogenesis. We describe here a novel GATA-4 -dependent molecular mechanism and therapeutic approach for post-MI HF. Moreover, we have identified 2 putative mechanisms, angiogenesis and CSC recruitment, whereby GATA-4 confers post-MI cardioprotection.
